Drone strike razes Indian‑affiliated pharmaceutical factory
New Delhi. A Russian‑operated drone hit the Kusum Group’s manufacturing complex in Sumy, Ukraine, collapsing the main structure, killing an engineer and injuring multiple staff members. The facility, which had continued operations throughout the war, sustained several blows that demolished its engineering wing and triggered an urgent evacuation.
Early estimates put the damage at around Rs 400 crore, though the company says a comprehensive audit is still pending. With such severe destruction, the plant is expected to stay shut for an undefined period.
Indian origins, Ukrainian presence
Kusum Group entered Ukraine in 1994, initially acting as a distributor of medicines sourced from India. By 2009 it had erected a full‑scale production site in Sumy, complementing its 2007 manufacturing base in India. Today the conglomerate markets more than 50 generic drugs across Ukraine, Uzbekistan, Kazakhstan and the Philippines, positioning itself as a Ukrainian pharma company with Indian roots.
Production persisted despite conflict – until now
Even amid ongoing hostilities, the Sumy plant kept supplying medicines to local and regional patients. The recent attack, however, has halted output and forced the group to consider relocating vulnerable production lines to its Indian facilities.
Ukrainian President Volodymyr Zelenskyy denounced the strike, confirming that a drone barrage targeted the pharmaceutical complex and resulted in a fatality. The episode highlights the growing peril facing civilian and commercial sites in war zones.
Broader implications
The loss of the Sumy plant threatens the availability of essential generics in the area and raises concerns about the robustness of cross‑border supply chains during armed conflict. A thorough assessment will reveal the full financial and operational impact on the Indian‑linked conglomerate.
